#United States #Chicago #FDA Clearance #Coreline Soft #AVIEW Aorta Metrics

Coreline Soft's Innovative Leap in Aortic Analysis

In a significant breakthrough for medical imaging, Coreline Soft has recently secured clearance from the U.S. Food and Drug Administration (FDA) for its innovative software, AVIEW Aorta Metrics. This marks an important milestone as Coreline Soft now holds a total of 13 FDA 510(k) clearances, effectively expanding its offerings within the U.S. medical imaging AI landscape.

Enhancing Cardiovascular Visualization

AVIEW Aorta Metrics is designed to revolutionize how healthcare providers analyze aortic dimensions using chest computed tomography (CT) scans. The software utilizes artificial intelligence to automatically segment the aorta and provide precise diameter measurements across varied anatomic regions. By classifying aortic zones and measuring their diameters, AVIEW Aorta Metrics allows for a systematic quantitative evaluation.

Healthcare professionals will benefit from additional features such as straightened CPR (curved planar reformation) views and comprehensive cross-sectional and 3D imaging options. This development not only broadens the quantitative capabilities of chest CT but also aligns perfectly with Coreline Soft's strategic multi-disease analysis approach based on chest CT imaging in the competitive U.S. market.

Meeting Growing Demand for Quantitative Data

The U.S. medical imaging AI sector is undergoing a transformation, with an increasing demand for extracting clinically significant information from existing CT scans. The traditional radiology workflows are evolving, demanding that insights gained from these scans seamlessly integrate into established Picture Archiving and Communication Systems (PACS). To meet this growing demand, Coreline Soft has engineered the AVIEW platform, allowing it to perform multistage analyses across various diseases from a single chest CT scan.

Coreline's AVIEW line includes products like AVIEW LCS and AVIEW Lung Nodule CAD, which provide robust support for lung nodule detection and quantitative analysis essential for lung cancer screening. The inclusion of AVIEW CAC adds valuable capabilities for assessing coronary artery calcium from standard chest CT scans, significantly enhancing clinical interpretability through quantitative scoring. This comprehensive suite of features underscores Coreline Soft's commitment to advancing cardiovascular imaging capabilities not just for pulmonary diseases but for a broader range of health metrics.

Broadening Horizons beyond Hospital Deployments

As the healthcare landscape shifts, Coreline Soft is transitioning its U.S. operations from singular hospital implementations to an integrated approach within clinical workflows and healthcare platforms. Collaborating with partners such as INFINITT North America, the company is advancing innovations in PACS-integrated, zero-click automation, thus allowing practitioners to benefit from continuous and seamless data analytics during their workflows.

Moreover, Coreline Soft is exploring further collaborations with companies like Optellum to enhance the management pathway for lung nodules, offering integrated solutions from detection to follow-up care. The collaboration with Oatmeal Health seeks to address lung cancer risk assessments, demonstrating Coreline Soft's innovative approach to healthcare technology and patient care.

What's Next? Presentation at RSNA 2026

Coreline Soft is set to showcase its cutting-edge AVIEW platform at the upcoming Radiological Society of North America (RSNA) 2026 conference scheduled from November 29 to December 3 at McCormick Place in Chicago, Illinois. Visitors at AI Showcase Booth #5138 can look forward to firsthand demonstrations of AVIEW's capabilities, including its lung nodule and coronary artery analysis solutions. With the conference theme focusing on transforming AI detection into tangible clinical implementations, Coreline Soft is well-positioned to illustrate how quantitative imaging insights can enhance real-world radiology workflows and facilitate comprehensive disease analysis.

Coreline Soft’s journey reflects a commitment not only to enhancing quantitative imaging technology but also to integrating more profound insights into everyday clinical practice. As the healthcare industry evolves, the implications of such technology become more pronounced, signaling an exciting future for AI in medical imaging.